PITTSBURGH, Oct. 29, 2026 /PRNewswire/ -- "I wanted to create a more convenient and discreet way for women to keep money and other small valuables close at hand," said an inventor from Lansford, Pennsylvania. "My idea would provide added security and peace of mind while allowing the wearer to travel more lightly."

InventHelp Invention Spotlight: POCKET BRA Could Help Women Securely Carry Small Personal Items

- Provides discreet storage for money and other small valuables

- Offers convenient access to essential personal items

- Helps reduce the risk of loose belongings becoming lost InventHelp Client's Invention for Women

Women may need a secure and convenient way to carry money, identification and other small personal belongings when a purse or wallet would be unnecessary or inconvenient. The POCKET BRA would address this concern by offering a discreet personal-storage option and could appeal to women and girls seeking convenience, security and greater freedom while traveling, attending events or completing everyday activities.

Licensing Opportunities for InventHelp 123Invent Client:

- The invention is available for licensing or sale to manufacturers or marketers who may wish to bring it to market

- For more information, visit www.pocketbra.net. Or contact Jose Baez at 272-296-7942 or email [email protected].

About InventHelp: Empowering Inventors with Tools, Guidance, and Potential Exposure

InventHelp is one of America's leading invention-service companies, helping inventors and entrepreneurs submit invention ideas to companies to attempt to obtain a good faith review.

Since 1984, the company has assisted clients with invention submission, prototype modeling services, invention websites, patent referral services, and more. InventHelp's team attempts to connect inventors with companies looking for new product ideas and provides services on how to present, promote, and protect inventions. Through its invention services, InventHelp provides confidentiality, step-by-step support, and help to innovators who wish to submit their inventions to industry. To learn more about InventHelp, visit InventHelp.com.

SOURCE InventHelp

Share this article

BALDWIN PARK, Calif., Oct. 29, 2026 /PRNewswire/ -- Wheelhouse is proud to announce the acquisition of All Star Garage Door, a family-owned residential and commercial garage door company serving communities across California and Utah. The deal marks Wheelhouse's second acquisition of 2026.

Founded in 2008, All Star Garage Door has built its reputation on quality garage door installation, service and repair, reflected in its tagline, "The Face of Fine Homes." Today, the company has more than 30 employees. In addition to serving Southern California, the Central Valley and the Central Coast, All Star expanded into Utah in 2024, bringing its services to the St. George and Park City communities.

"Ryan Salinas and his team have built something special at All Star," said Ron Avidan, CEO of Wheelhouse. "Their craftsmanship and customer care align with our values, and we're thrilled to welcome them to our growing family of brands."

"Our success has always been driven by the dedication of our All Star employees, the trust of our customers, the support of our partners and the relationships we've built over the years," said Ryan Salinas, owner of All Star Garage Door. "I'm excited for All Star to begin this next chapter in partnership with Wheelhouse, which creates tremendous opportunities for continued growth and long-term success."

Wheelhouse is actively seeking add-on opportunities with owner-operated garage door businesses across the United States. To learn more about partnering with Wheelhouse, contact Lucas Lebrao, VP of Corporate Development, at [email protected] or visit www.wheelhouse-brands.com/contact.

About Wheelhouse

Wheelhouse, backed by Trivest Partners, is a national growth platform built for the residential and commercial garage door service and installation industry. The company partners with established, founder-led businesses across the United States, providing the systems, leadership and infrastructure they need to grow. For more information, visit www.wheelhouse-brands.com.

Contact:

Megan Burland

Marketing Manager

[email protected]

SOURCE Wheelhouse GD Buyer LLC

Share this article

Angel Investor Forum leads round as Urologic Design prepares for first-in-human study

BRANFORD, CT, Oct. 29, 2026 /PRNewswire/ -- Urologic Design, a start-up commercializing innovations in urology care, today announced the closing of a $1.2M pre-seed fundraise. The equity funding will help the company develop its first product, a patented medical device for managing urinary incontinence. The investment will also support continued R&D activities, regulatory work, and preparation for the company's first-in-human clinical study.

The oversubscribed round was led by Angel Investor Forum, Connecticut's primary angel group, and joined by HBS Alumni Angels of Boston, Haven Founders Fund, Connecticut Innovations, and Yale Angels, in addition to several individual investors.

"AIF invests in companies addressing meaningful unmet needs with differentiated solutions," said Matthew Stannard, Life Sciences Lead at Angel Investor Forum. "Urologic Design impressed us with its approach to bridging the gap between absorbent products and surgery for managing urinary incontinence. We are excited to support the company as it advances toward first-in-human testing, an important step on the path to commercialization."

The funds will enable Urologic Design to further refine and test its first productâa urethral occlusion device for men. The company has already developed a working prototype, secured IP protection, and conducted extensive bench testing. Preparations are beginning for an initial clinical study involving a small cohort of men with stress urinary incontinence.

"For the 25 million people living with urinary incontinence in the United States, the available options are uncomfortable, cumbersome, and difficult to incorporate into everyday life," says Dr. David Hesse, Co-Founder and Chief Scientific Officer of Urologic Design. "We founded Urologic Design to develop a simple, temporary solution that gives people greater dignity, control, and confidence in managing leakageâall while fitting naturally into their daily lives."

About Urologic Design

Urologic Design is a start-up that commercializes innovations in urology care. The company was founded in 2022 by Dr. David Hesse, who is the Chief Scientific Officer and an Associate Professor of Urology at the Yale School of Medicine. Urologic Design is headquartered in Branford, CT. For more information, visit www.urologicdesign.com.

Urologic Design Media Contact

[email protected]

SOURCE Urologic Design

Share this article

HAUPPAUGE, N.Y., Oct. 29, 2026 /PRNewswire/ -- SightMD, a leading multi-specialty eye care provider serving communities throughout New York, New Jersey, Connecticut, Pennsylvania and Massachusetts, is proud to announce that it has been named a winner in the 2026 The City's Best competition in three categories:

- LASIK Surgery Practice

- Optomet Practice

- Optometrist

- Ophthalmologist

The City's Best is a community-driven competition that invites the public to nominate and vote for their favorite Manhattan businesses and professionals across a variety of categories. The top nominees advance to the official ballot, and the organization receiving the most votes is named the first-place winner in its category.

SightMD's recognition across three eye care categories reflects the confidence patients and community members place in its doctors, clinical teams and staff. It also highlights the organization's ongoing commitment to delivering comprehensive, high-quality eye care using advanced technology and a patient-first approach.

"We are incredibly honored to receive this recognition in three important areas of eye care," said Jonathan Ellant, MD, SightMD surgeon. "These awards reflect the dedication of our doctors, clinical teams and staff, who work every day to provide an exceptional experience and the highest level of care for our patients. We are especially grateful to everyone who voted and continues to place their trust in SightMD."

From routine eye examinations and the management of complex eye conditions to advanced cataract surgery and vision correction procedures such as LASIK, SightMD offers patients access to a broad range of services within one trusted network.

SightMD thanks its patients, employees and surrounding communities for helping make this achievement possible. The organization remains committed to expanding access to exceptional eye care and helping patients enjoy clearer vision at every stage of life.

For more information or to schedule an appointment, please visit www.SightMD.com or call 1-855-295-4144.

SightMD is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer, Brad Kligman, at [email protected]

About The City's Best

The City's Best is an annual competition recognizing outstanding businesses and professionals throughout Manhattan. Members of the public nominate their favorite local organizations in categories spanning health and wellness, food and dining, education, professional services, shopping, entertainment and more. The leading nominees advance to a public voting round, with one first-place winner selected in each category based on the highest number of votes. The program is promoted by Schneps Media across its network of local print and digital publications. Additional information is available through The City's Best.

About SightMD

SightMD is a rapidly-growing integrated ophthalmic group, offering patients access to over 100 doctors through the convenience of 38 locations across New York. SightMD's track record of providing clinically-excellent care spans over 50 years, and its services include LASIK laser vision correction, laser cataract surgery and lens implantation, oculoplastic surgery, general eye exams, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD as well as SightMD Connecticut, SightMD New Jersey, and SightMD Pennsylvania. For more information about SightMD, please visit sightmd.com

SOURCE SightMD

Share this article

MILWAUKEE, Oct. 29, 2026 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received almost 1,200 abstract submissions in 2026, and has announced titles and authors for the accepted Late-breaking Abstracts (LBA). Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC's upcoming 41st Annual Meeting & Pre-Conference Programs taking place Nov. 4â8, 2026, in Phoenix, AZ and virtually.

SITC also invites you to attend the virtual press briefing of the society's 41st Annual Meeting (SITC 2026) beginning at 12â1:30 p.m. MT on Wednesday, Nov. 4, 2026.

The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research. Data shared during the press briefing may be embargoed to a later date and time during the Annual Meeting and that information will be shared during the presentation. For more information, please review the SITC 2026 Media Policy.

The schedule of presentations and press briefing presenters are listed in order below:

- Abstract #553: Adoptive transfer of T cells engineered with mutant p53-specific TCRs for the treatment of metastatic solid epithelial cancers: interim report of ongoing phase II clinical trial

- Presenter: Sanghyun Kim, PhD â National Cancer Institute

- Abstract #323: Adaptive anti-CAR immunity compromises the durability of GD2-CAR T cell therapy in diffuse midline glioma

- Presenter: Kevin Reynolds, MD â Stanford Cancer Institute

- Abstract #566: OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: Pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen

- Presenter: Rodabe Amaria, MD â The University of Texas MD Anderson Cancer Center

- Abstract #1176: Adoptive Immunotherapy with Effector T Lymphocytes that were Generated Following Cancer Neoantigen Vaccination of MGMT Unmethylated Glioblastoma Multiforme Patients is Associated with Survival Benefit

- Presenter: Patrick Grogan, MD â Moffitt Cancer Center

- Abstract #828: Oncolytic Adenoviruses Induce Tertiary Lymphoid Structures in Brain Tumors to Promote Durable Antitumor Immunity

- Presenter: Hong Jiang, PhD â The University of Texas MD Anderson Cancer Center

- Abstract #501: Phase 1b trial of intratumoral administration of the seasonal influenza vaccine in patients with melanoma

- Presenter: Ian Garbarine, MD â The Ohio State University; The Ohio State University Comprehensive Cancer Center

- Abstract #1182: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors

- Presenter: Justin Moser, MD â HonorHealth Research Institute

- Abstract #1185: Safety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1âResistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies

- Presenter: Kai He, MD, PhD â University of Texas Mays Cancer Center at San Antonio

ADDITIONAL DETAILS: 

Participating members of the media will have the opportunity to submit questions for up to three minutes following each presentation. To attend this press briefing, you must register as a member of the press for SITC 2026. To register, please visit https://www.sitcancer.org/2026/press/press-registration.

After registration is confirmed, you will receive instructions for the briefing. For more information regarding SITC 2026, please visit the Annual Meeting website at http://www.sitcancer.org/2026.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, Bluesky, Facebook and YouTube.

SOURCE Society for Immunotherapy of Cancer (SITC)

Share this article

egnite's CardioCare® Platform is deploying Pathway Labs' recently cleared ECG algorithm at Stamford Health to more effectively prioritize and coordinate care for echo-ready patients.

ALISO VIEJO, Calif., Oct. 29, 2026 /PRNewswire/ -- egnite, Inc., a technology company advancing guideline-directed cardiovascular care and real-world evidence, today announced a clinical pilot with Pathway Labs and Stamford Health (Stamford, Connecticut) to deploy Pathway's novel electrocardiogram (ECG) screening results within egnite's CardioCare® platform.

EchoNext, developed by Pathway Labs and recently cleared by the U.S. Food and Drug Administration, will analyze 12-lead ECG waveforms at Stamford Health for signals associated with a range of cardiac conditions â including signs of structural heart disease, heart failure, and pulmonary hypertension. It is the first AI tool cleared in the U.S. to screen for this breadth of structural heart conditions from a single ECG.

Detection alone does not change care. ECG-based screening can identify large numbers of patients who could warrant follow-up, but an AI flag is only one signal in a patient's record. The CardioCare platform, in use across more than 80 heart programs, helps close that gap. After EchoNext flags a study, the CardioCare platform evaluates the finding alongside the patient's longitudinal record â prior diagnoses, labs, and history â to surface a focused, pre-qualified group of patients likely to benefit from echocardiographic follow-up (echo-ready patients) within the workflows care teams already use. Because CardioCare tracks each patient from initial flag through imaging, evaluation, and treatment decision, the pilot will also measure the downstream clinical impact of ECG-based screening â including echo completion rates and time to specialist evaluation. CardioCare is designed to integrate screening outputs from multiple sources into a single clinical workflow; Pathway Labs is the first algorithm partner to go live.

"AI can identify patients at risk, but that's only the first step. The real challenge is making sure those patients receive the appropriate follow-up evaluation and treatment without creating additional burden for already busy clinical teams. CardioCare is designed to bridge that gap by providing the clinical context and workflow needed to move patients efficiently from detection to diagnosis and, ultimately, appropriate treatment," said Rahul Sharma, MD, MBBS, FRACP, Director of Structural Interventions and Associate Director of the Cardiac Catheterization Laboratory at Stanford Health Care, and Senior Medical Advisor of egnite. "This pilot with Pathway Labs is exciting because it will allow us to evaluate the entire care pathway to quantify how this AI can meaningfully improve real-world patient care."

"The team at Stamford Health is excited to bring this novel technology to our patients and strengthen how we screen for heart disease. Since 2022, we've used the CardioCare platform to identify and evaluate nearly 300 patients with significant heart disease who were not otherwise on a path to treatment," said Arzhang Fallahi, MD, Director of Structural Heart, Stamford Health. "Bringing Pathway Labs' AI-enabled ECG screening into our program extends that approach to the tens of thousands of ECGs we perform each year, giving us the chance to catch heart disease even earlier."

"This new and exciting algorithm will vastly expand our current AI programs in cardiac imaging and improve quality of care for our patients," said David Hsi, MD, Chief of Cardiology and Co-Director of Heart & Vascular Institute at Stamford Health.

"This technology started as a research effort and has demonstrated strong patient impact in the FDA validation studies. Partnering with egnite lets us validate the algorithm in real-world practice across several health systems â and we're energized that Stamford Health is the first. egnite's clinical workflow infrastructure and reach across 80+ heart programs make them the ideal partner to take this from regulatory milestone to the bedside," said Pierre Elias, MD, CEO of Pathway Labs.

Edwards Lifesciences is contributing funding to the pilot as part of a collaboration with egnite and Pathway Labs to advance earlier identification of patients with structural heart disease.

About egnite, Inc.

egnite, Inc. is a technology company advancing guideline-directed cardiovascular care and real-world evidence. egnite's CardioCare® platform is deployed at more than 80 heart programs, drawing on data from more than 1,200 cardiovascular care facilities in its network, to identify and prioritize cardiovascular patients. CardioCare combines practical AI, clinical logic aligned to ACC/AHA guidelines, and workflow integration to help hospitals move more patients into evidence-based care pathways. The egnite Registry, built on de-identified EHR data from approximately 15.7 million patients and 6 million echo reports, gives life sciences and research teams a longitudinal view of the patient journey. The company is headquartered in Aliso Viejo, California. For more information, visit www.egnitehealth.com.

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of cardiovascular diseases.

About Pathway Labs

Pathway Labs builds AI that helps clinicians catch heart disease earlier, starting with EchoNext, a screening tool that reads routine ECGs to identify patients who should go on to an echocardiogram. Started by Dr. Pierre Elias and a world-leading team of cardiac AI researchers from Columbia University Irving Medical Center and NewYork-Presbyterian, Pathway Labs is dedicated to bringing rigorously validated cardiovascular AI out of the research setting and into everyday clinical care to help patients live longer, healthier lives.

About Stamford Health

Stamford Health is a non-profit independent health care system serving Fairfield County, Connecticut. With more than 4,100 employees committed to delivering expert, compassionate, person-centered care, patients and their families receive an array of health and wellness services through the system's 305-bed Stamford Hospital; 40 Stamford Health Medical Group offices; and a growing number of ambulatory locations.

Stamford Health consistently receives top tier clinical and safety recognitions from U.S. News & World Report, Leapfrog, The American Nurses Credentialing Center, Planetree, Centers for Medicare & Medicaid Services and Castle Connolly, and is a Certified⢠Great Place to Work. Stamford Health brings specialized care to the community through partnerships with leading academic medical centers including Columbia University Vagelos College of Physicians and Surgeons and Dana-Farber Brigham Cancer Center and highly regarded care providers like Hospital for Special Surgery and Oula Health.

Through the Stamford Hospital Foundation, Stamford Health receives support to sustain core medical programs, acquire the latest technology and enhance patient-care overall.

For more information, visit StamfordHealth.org. Like us on Facebook and follow us on Instagram, LinkedIn, and YouTube.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.

Discover more at www.edwards.com.

SOURCE egnite Health

Share this article

Process orchestration leader earns highest unclassified level of authorization to deliver secure, intelligent automation for mission-critical warfare operations

MCLEAN, Va., Oct. 29, 2026 /PRNewswire/ -- Appian today announced that the Appian Defense Cloud (ADC) achieved Impact Level 5 (IL5) Provisional Authorization to Operate (PA) from the United States Department of War (DOW). Building on Appian's IL5 Appian Government Cloud (AGC) offering, this accreditation enables DOW agencies to deploy mission-critical workloads using Appian's intelligent process automation innovations with enterprise-grade security.

"Achieving IL5 for our next generation platform - ADC marks a significant milestone for Appian in providing the DOW with mature and secure intelligent process automation to support warfighter operations," said Michael Beckley, Chief Technology Officer at Appian. "The production-ready platform represents an evolution of Appian's long-standing defense capabilities, bringing modern agentic intelligence and process orchestration directly to mission operations with enterprise-grade guardrails."

Appian's defense heritage began with its contract to architect Army Knowledge Online (AKO) more than two decades ago, which grew into one of the world's largest military intranets. As one of the first cloud service providers to achieve FedRAMP authorization in 2015, Appian has demonstrated continuous mastery of meeting continuous monitoring and security compliance requirements across public sector environments.

This latest designation recognizes the operational maturity of the Appian Platform and the DOW's continued trust for it to provide industry-leading security and availability across high-impact warfare operations. With IL5 designation, ADC can store and process the DOW's highest-sensitivity unclassified information, mission-critical data, and unclassified national security systems.

Scale and deployment across US defense

Appian's defense footprint scaled almost 4x in deployment volume over the last 12 months. Today, Appian supports:

- 2,000,000+ active DOW & IC users relying on the platform for daily operations.

- 100+ mission platforms running mission-critical automation.

- Supporting key operational communities, including contract writing, legal case management, intelligence and security, foreign military sales, and logistics and maintenance.

Key fielded capabilities include 12 prominent Army programs in production, including the Total Army Combat and Training Munitions Information System (TACTMIS) for the US Army. Created in 110 days from contract award to support more than 10,000 active users worldwide, TACTMIS delivers speed and value for training and operational missions. By unifying munitions management processes across the Active Army, Army National Guard, US Army Reserve, and joint partners, TACTMIS provides the scale, security, and visibility needed to support Army-wide readiness and senior-leader decision-making.

Defense-grade capabilities for DOW-compliance

Built on Appian's next-generation cloud-native architecture, ADC delivers complete commercial platform capabilities within a DOW-compliant boundary:

- Orchestrated agentic intelligence: Native capabilities for agent-assisted workflow creation, intelligent document processing (IDP), generative capabilities, and agentic insights.

- Data fabric: Connects disparate data sources without moving core records, giving agents and users immediate context.

- Process intelligence: Real-time process monitoring and analytics to track operational efficiency and auditability.

The US Department of War and every service branch of the US Armed Forces trust Appian to improve government processes. Learn how Appian can help transform your operations to increase efficiency and productivity: https://appian.com/defense.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding future product capabilities, strategic plans, and industry growth, are forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Appian undertakes no obligation to update forward-looking statements.

About Appian

Appian provides AI automation for the most important business processes at the world's largest organizations.

On the Appian Platform, customers build AI-powered processes that accelerate work, reduce cost, and manage risk. Our platform is known for its unique power, reliability, and scale. We've been automating processes for more than 25 years and have proven expertise in enterprise operations. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, YouTube, Instagram, Facebook, and X.

SOURCE Appian

Share this article

United Premier Soccer League Names Corgi Insurance Its Official Insurance Partner

The partnership provides comprehensive insurance coverage to more than 900 Member Clubs and 37,000 registered participants nationwide.

SAN FRANCISCO, Oct. 29, 2026 /PRNewswire/ -- Corgi Insurance, an AI-native insurance carrier and financial infrastructure company, announced a three-year partnership with the United Premier Soccer League (UPSL), naming Golden by Corgi the league's official insurance and protection partner.

Effective September 30, 2026, the partnership provides insurance coverage for the UPSL, its more than 900 Member Clubs, and approximately 37,000 registered players, coaches, and officials across sanctioned competitions nationwide.

Through Golden, Corgi is bringing its integrated insurance infrastructure to one of the largest club soccer leagues in the United States, simplifying how organizations obtain coverage, manage risk, and handle claims.

Beyond insurance coverage, the partnership is designed to simplify the administrative processes that clubs and league officials navigate throughout the season.

Member Clubs will also have access to the Golden Standard, a safety and risk management resource hub providing expert-backed guidance to help organizations maintain safer playing environments.

"UPSL is one of the largest club soccer platforms in the country, and it deserves a program built for how it actually operates," said Mike T. Brown, Executive Partner at Golden by Corgi. "As a full-stack carrier, we do better when the sport stays safe, so we are with UPSL and its clubs all year, not just at renewal."

The UPSL partnership is the latest in a series of national league and governing body partnerships established by Golden in 2026 as Corgi continues to expand its insurance offerings across new industries.

UPSL Member Clubs can access information about their coverage, request certificates of insurance, and report incidents at premier.upsl.com/insurance.

About the United Premier Soccer League

UPSL is a national professional and semi-professional soccer league with more than 900 Member Clubs and approximately 37,000 registered participants across the United States, including men's, women's, and youth divisions. Learn more at premier.upsl.com.

About Golden by Corgi

Golden is a full-stack insurance program for sports and entertainment organizations, backed by Corgi. Golden issues, administers, and services coverage for national governing bodies, leagues, teams, and events under one roof.

Media Contact

Corgi Press

[email protected]

SOURCE Corgi

Share this article

The first woman to lead Philips in Latin America brings more than 20 years of global healthcare leadership to Keikku.

AMSTERDAM, Oct. 29, 2026 /PRNewswire/ -- Lapsi Health, the Dutch clinical AI company behind Keikku, today announced the appointment of Fabia Tetteroo-Bueno to its Board of Directors. The former Senior Vice President and General Manager of Philips Latin America will guide Lapsi's strategy and partnerships as Keikku scales across the region.

The appointment follows major moves for Keikku in Latin America, from its office in Santiago to its collaborations with the SMC and SOMEIC.

A Global Leader With Deep Roots in Latin America

Born in Brazil, Tetteroo-Bueno built her career across three continents at Royal Philips. In 2020 she became Senior Vice President and General Manager of Philips Latin America, the first woman to lead the company in the region, and steered its healthcare strategy through the COVID-19 pandemic with a clear mission: widening access to quality care. She later held senior global commercial roles at Philips, including Head of Global Sales for the Software business.

In Their Words

"Fabia has spent her career proving that health technology only matters when it reaches people," said Jhonatan Bringas Dimitriades, MD, CEO and co-founder of Lapsi Health. "Having her on our board as Keikku deepens its presence across the region is a turning point for us."

"I joined Lapsi Health because I believe validated, certified clinical technology belongs in Latin America, not only in the U.S. and Europe," said Fabia Tetteroo-Bueno. "Keikku is CE-certified and built to the highest standards of safety and quality, and I want doctors across the region to have access to that same rigor."

Why Latin America, Why Now

Latin America is one of Keikku's fastest-growing markets. There, Keikku leads with three offerings built for Spanish- and Portuguese-speaking clinicians:

- Keikku Scribe, ambient AI that turns patient conversations into structured clinical notes in real time.

- Keikku Reference, AI-powered clinical decision support at the point of care.

- Keikku Telemedicina, the same tools for virtual consultations.

"Behind Keikku is a platform that takes over documentation and paperwork, giving clinicians back what matters most: time with their patients," Tetteroo-Bueno added. "I believe deeply in this technology and in the roadmap ahead, and I'm proud to support Lapsi in bringing it to Latin America."

About Lapsi Health and Keikku

Founded in 2022 in Amsterdam, Lapsi Health builds Keikku, a clinical AI platform that combines an FDA-cleared ambient microphone system with an AI Suite for documentation, clinical reference and auscultation. Lapsi is ISO 13485 certified, its AI Scribe is CE MDR Class I, and Keikku is deployed at leading institutions in Europe and the USA.

SOURCE Keikku; Lapsi Health

Share this article

DALLAS, Oct. 29, 2026 /PRNewswire/ -- Texas-based consultancy Turner, Mason & Company today announced the release of its Fall 2026 Outlooks on the energy market, providing medium- and long-term analysis of crude and refined products, heavy crude markets, renewable fuels and regulations and worldwide refinery construction.

Published each spring and fall, Turner, Mason & Company's Outlooks combine market data, project intelligence and fundamental analysis to evaluate supply and demand, trade flows, regulatory developments, refining margins and investment trends.

The four Fall 2026 Outlooks provide actionable data and fundamental analysis across key areas of the industry:

- Crude and Refined Products, examining how geopolitical disruption, secure logistics, inventory rebuilding and emerging-market demand are reshaping crude and refined-product balances.

- Regulatory and Renewable Fuels, assessing evolving biofuel policy and regulation, RIN and RVO dynamics, and the outlook for ethanol, biomass-based diesel, renewable diesel and sustainable aviation fuel.

- Global Heavy Crude Oil Market, evaluating regional production and export availability, including Canadian growth and TMX-related flows and the potential recovery of Venezuelan production.

- Worldwide Refinery Construction, tracking announced and probable refinery projects and their timing, crude slates, product yields and capital-cost trends.

"Crude availability means little if supply cannot move safely, reliably and cost-effectively," said Sandeep S. Sayal, vice president of research and consulting. "Between geopolitical turmoil, shifting trade flows and the impact of Canada's TMX expansion, market fundamentals are pivoting toward Western Hemisphere heavy crude. For refiners, feedstock decisions now hinge on route security, freight and logistical flexibility just as much as quality and price."

While logistics inefficiencies, inventory rebuilding and energy-security premiums may persist, the Outlooks do not assume that today's disruptions permanently alter long-term supply-and-demand trends; more information about the Fall 2026 reports from Turner, Mason & Company can be found under the subscriptions section at turnermason.com.

About Turner, Mason & Company

Based in Dallas and Houston, Turner, Mason & Company provides technical, commercial and strategic consulting services to clients globally in the crude oil, midstream, refining, refined products and biofuels industries. Its services support the downstream and midstream segments of the petroleum industry with core competencies in market analysis, company and industry analyses, technical and commercial support in mergers and acquisitions, transaction due diligence, economic, feasibility and market analyses, expert witness as well as attestations and fuels regulatory support. Information about the company is available at turnermason.com.

SOURCE Turner, Mason & Company

Share this article